Breast Neoplasms Clinical Trial
Official title:
Tamoxifen Pharmacogenomics and the Prevention of Recurrent Breast Cancer
This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.
Tamoxifen is a non-steroidal hormonal drug with weak estrogen agonist and potent estrogen
antagonist actions. The liver CYP450 metabolic enzyme systems are responsible for
metabolizing tamoxifen (the pro-drug form) into its active metabolites. A secondary
tamoxifen metabolite known specifically as 4-hydroxy-N-desmethyl-tamoxifen or endoxifen is
recognized as the principal potent metabolite responsible for tamoxifen suppression of
estrogen-dependent cell proliferation, the stimulus for breast tumor growth.
Biotransformation to endoxifen is through the CYPP450 2D6 pathway; therefore, the ability of
tamoxifen to effectively suppress breast cancer is jeopardized in patients with certain
CYP450 2D6 genetic variants and/or those receiving drug therapy that are known to alter
CYP450 2D6 function (i.e., with CYP450 2D6 inhibitors).
Four phenotype expressions classified as ultrarapid, extensive, intermediate and poor
metabolizers can be discerned from genotype testing for CYP450 2D6 activity. Patients with
normal metabolic activity are known as extensive metabolizers given that they possess either
two (genotype = wt/wt) or one (genotype = wt/vt) functioning CYP450 2D6 gene that converts a
sufficient amount of tamoxifen in to its active form. Intermediate metabolizers have at
least some or very low CYP450 2D6 activity and there does not appear to be uniform consensus
on the impact of this phenotype on tamoxifen drug disposition. Poor metabolizers lack any
functional CYP450 2D6 activity, and therefore, they do not metabolize tamoxifen enough to
produce sufficient endoxifen activity. Approximately 10% of patients (7% of Caucasians and
1-3% of other ethnic groups) are poor metabolizers with a complete absence of CYP450 2D6
activity.
The genetic variants associated with diminished or absent CYP450 2D6 activity are found on
CYP450 2D6 alleles *3, *4, *5, *6 and *10. The *3, *4, *5 and *6 alleles, when present in
variant form (genotype = vt/vt), account for approximately 97% of nonfunctional CYP450 2D6
variants in caucasians. Of these mutations, those in CYP450 2D6 *4 are most significant for
endoxifen.
Poor metabolizer phenotype has been associated with worse relapse-free breast cancer
survival and increased risk (up to three times that of intermediate metabolizer status who
have some CYP450 2D6 activity) for breast cancer recurrence.
Diagnostic technology now exists to aid in determining which tamoxifen patients are
potentially receiving suboptimal treatment from existing alterations in one or more of the
approximately 80 alleles of the gene coding for the CPYP450 2D6 enzyme. Recognition of this
phenomenon provides physicians and their patients the opportunity for considering the use of
other anti-estrogen drugs such as aromatase inhibitors in women whose CYP450 2D6 phenotype
puts them at risk for poor response to tamoxifen therapy.
This study will use this diagnostic technology to determine a patient's phenotype provide
additional clinical information and alternative drug therapies to the patient's physician.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03698942 -
Delphinus SoftVueâ„¢ ROC Reader Study
|
||
Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 |